ATE406365T1 - Substituierte indazolyl(indolyl)maleimid-derivate als kinase inhibitoren - Google Patents

Substituierte indazolyl(indolyl)maleimid-derivate als kinase inhibitoren

Info

Publication number: ATE406365T1
Authority: AT; Austria
Prior art keywords: sub; kinase inhibitors; kinase; indolyl; compounds
Prior art date: 2003-06-13

Application number

AT04754066T

Other languages

English (en)

Inventor

Han-Cheng Zhang

Bruce Maryanoff

Hong Ye

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-13

Filing date

2004-06-01

Publication date

2008-09-15

2004-06-01 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2008-09-15 Application granted granted Critical

2008-09-15 Publication of ATE406365T1 publication Critical patent/ATE406365T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Hematology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Virology (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Ophthalmology & Optometry (AREA)
Molecular Biology (AREA)

AT04754066T 2003-06-13 2004-06-01 Substituierte indazolyl(indolyl)maleimid-derivate als kinase inhibitoren ATE406365T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US47851603P	2003-06-13	2003-06-13

Publications (1)

Publication Number	Publication Date
ATE406365T1 true ATE406365T1 (de)	2008-09-15

Family

ID=33551833

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04754066T ATE406365T1 (de)	2003-06-13	2004-06-01	Substituierte indazolyl(indolyl)maleimid-derivate als kinase inhibitoren

Country Status (22)

Country	Link
US (1)	US7439363B2 (de)
EP (1)	EP1654255B1 (de)
JP (1)	JP2007500748A (de)
KR (1)	KR20060021890A (de)
CN (1)	CN1832940A (de)
AT (1)	ATE406365T1 (de)
AU (1)	AU2004251178A1 (de)
BR (1)	BRPI0411366A (de)
CA (1)	CA2529353A1 (de)
CO (1)	CO5650246A2 (de)
CR (1)	CR8148A (de)
DE (1)	DE602004016174D1 (de)
EA (1)	EA200600032A1 (de)
EC (1)	ECSP056222A (de)
ES (1)	ES2311161T3 (de)
HR (1)	HRP20050991A2 (de)
IL (1)	IL172456A0 (de)
IS (1)	IS8174A (de)
NO (1)	NO20060145L (de)
RS (1)	RS20050915A (de)
WO (1)	WO2005000836A1 (de)
ZA (1)	ZA200600294B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ20031594A3 (cs)	2000-12-08	2004-06-16	Ortho-Mcneil Pharmaceutical, Inc.	Pyrrolinové sloučeniny substituované indazolylovou skupinou jako inhibitory kinázy
JP2005529918A (ja) *	2002-05-08	2005-10-06	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	置換されたピロリンキナーゼ阻害剤
AU2003240517A1 (en) *	2002-06-05	2003-12-22	Janssen Pharmaceutica N.V.	Substituted pyrrolines as kinase inhibitors
CA2520590A1 (en) *	2003-03-27	2004-11-04	Janssen Pharmaceutica, N.V.	Substituted pyrroline kinase inhibitors
AU2006282896A1 (en)	2005-08-26	2007-03-01	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
EP2258357A3 (de)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenese mit Acetylcholinesterasehemmer
CA2624378A1 (en) *	2005-09-29	2007-04-12	Janssen Pharmaceutica N.V.	Macroheterocylic compounds as kinase inhibitors
WO2007047978A2 (en)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation of neurogenesis by pde inhibition
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2377531A2 (de)	2006-05-09	2011-10-19	Braincells, Inc.	Neurogenese mittels Angiotensin-Modulation
KR101284836B1 (ko)	2006-05-25	2013-07-10	삼성전자주식회사	이동통신시스템에서 자원 할당 맵 구성 방법
BRPI0715160A2 (pt)	2006-08-08	2013-06-11	Sanofi Aventis	imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
WO2008037266A1 (en) *	2006-09-25	2008-04-03	Universite Libre De Bruxelles	Inhibitors of conventional protein kinase c isozymes and use thereof for treating inflammatory diseases
US8193236B2 (en)	2006-12-19	2012-06-05	Novartis Ag	Indolylmaleimide derivatives processes for their production and pharmaceutical compositions
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8470841B2 (en)	2008-07-09	2013-06-25	Sanofi	Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
ES2443016T3 (es)	2009-08-26	2014-02-17	Sanofi	Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
RU2441000C2 (ru) *	2009-11-27	2012-01-27	Общество с ограниченной ответственностью "Молекулярные Технологии"	4-(1-(4-(4-метоксифенилтио)-2,5-диоксо-2,5-дигидро-1н-пирро-3-ил)-1н-индол-3-ил)бутилкарбамимидотиоат и способ его применения
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
ES2387359B1 (es) *	2011-02-25	2013-08-01	Consejo Superior De Investigaciones Científicas (Csic)	Inhibidores de GSK-3 útiles en enfermedades neurodegenerativas, inflamatorias, cáncer, diabetes y en procesos regenerativos
WO2012120050A1 (de)	2011-03-08	2012-09-13	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en)	2011-03-08	2014-10-28	Sanofi	Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8809325B2 (en)	2011-03-08	2014-08-19	Sanofi	Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2683703B1 (de)	2011-03-08	2015-05-27	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683705B1 (de)	2011-03-08	2015-04-22	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en)	2011-03-08	2014-04-29	Sanofi	Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (de)	2011-03-08	2014-12-17	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683701B1 (de)	2011-03-08	2014-12-24	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
CN102344443A (zh) *	2011-07-15	2012-02-08	南开大学	点击化学合成开环马来酰亚胺类化合物及其在治疗疾病中的应用
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (de)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamidderivate als kinaseinhibitoren
CN103622964B (zh) *	2013-12-04	2015-09-23	李强	Trigolutesins A在治疗或预防急性心衰药物中的应用
US10220408B2 (en) *	2016-09-12	2019-03-05	The Boeing Company	Variable radius print head end effector
CN108586432B (zh) *	2018-05-31	2020-08-25	温州医科大学	一种3-(吲哚-5-基)-吲唑衍生物及其应用
AU2020218366A1 (en)	2019-02-08	2021-09-16	Frequency Therapeutics, Inc.	Valproic acid compounds and Wnt agonists for treating ear disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ280738B6 (cs) *	1988-02-10	1996-04-17	F. Hoffmann - La Roche And Co., Aktiengesellschaft	Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
GB8904161D0 (en) *	1989-02-23	1989-04-05	Hoffmann La Roche	Substituted pyrroles
US5624949A (en) *	1993-12-07	1997-04-29	Eli Lilly And Company	Protein kinase C inhibitors
SE9603283D0 (sv) *	1996-09-10	1996-09-10	Astra Ab	New compounds
AU4929999A (en)	1998-07-30	2000-02-21	Japan Tobacco Inc.	Disubstituted maleimide compounds and medicinal utilization thereof
DE69922526T2 (de)	1998-10-08	2005-06-02	Smithkline Beecham Plc, Brentford	3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
CZ20031594A3 (cs) *	2000-12-08	2004-06-16	Ortho-Mcneil Pharmaceutical, Inc.	Pyrrolinové sloučeniny substituované indazolylovou skupinou jako inhibitory kinázy
JP2005529918A (ja) *	2002-05-08	2005-10-06	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	置換されたピロリンキナーゼ阻害剤
AU2003240517A1 (en) *	2002-06-05	2003-12-22	Janssen Pharmaceutica N.V.	Substituted pyrrolines as kinase inhibitors
WO2003104222A1 (en) *	2002-06-05	2003-12-18	Janssen Pharmaceutica N.V.	Bisindolyl-maleimid derivatives as kinase inhibitors
CA2520590A1 (en) *	2003-03-27	2004-11-04	Janssen Pharmaceutica, N.V.	Substituted pyrroline kinase inhibitors

2004
- 2004-06-01 US US10/858,212 patent/US7439363B2/en not_active Expired - Fee Related
- 2004-06-01 EP EP04754066A patent/EP1654255B1/de not_active Expired - Lifetime
- 2004-06-01 AU AU2004251178A patent/AU2004251178A1/en not_active Abandoned
- 2004-06-01 AT AT04754066T patent/ATE406365T1/de not_active IP Right Cessation
- 2004-06-01 BR BRPI0411366-7A patent/BRPI0411366A/pt not_active IP Right Cessation
- 2004-06-01 WO PCT/US2004/017375 patent/WO2005000836A1/en not_active Ceased
- 2004-06-01 JP JP2006533550A patent/JP2007500748A/ja not_active Withdrawn
- 2004-06-01 EA EA200600032A patent/EA200600032A1/ru unknown
- 2004-06-01 CN CNA200480022892XA patent/CN1832940A/zh active Pending
- 2004-06-01 CA CA002529353A patent/CA2529353A1/en not_active Abandoned
- 2004-06-01 DE DE602004016174T patent/DE602004016174D1/de not_active Expired - Fee Related
- 2004-06-01 HR HR20050991A patent/HRP20050991A2/xx not_active Application Discontinuation
- 2004-06-01 RS YUP-2005/0915A patent/RS20050915A/sr unknown
- 2004-06-01 KR KR1020057023946A patent/KR20060021890A/ko not_active Withdrawn
- 2004-06-01 ES ES04754066T patent/ES2311161T3/es not_active Expired - Lifetime
2005
- 2005-12-08 IL IL172456A patent/IL172456A0/en unknown
- 2005-12-09 IS IS8174A patent/IS8174A/is unknown
- 2005-12-13 CR CR8148A patent/CR8148A/es not_active Application Discontinuation
- 2005-12-13 EC EC2005006222A patent/ECSP056222A/es unknown
- 2005-12-19 CO CO05127381A patent/CO5650246A2/es not_active Application Discontinuation
2006
- 2006-01-10 NO NO20060145A patent/NO20060145L/no not_active Application Discontinuation
- 2006-01-12 ZA ZA200600294A patent/ZA200600294B/xx unknown

Also Published As

Publication number	Publication date
NO20060145L (no)	2006-03-07
CA2529353A1 (en)	2005-01-06
AU2004251178A1 (en)	2005-01-06
HRP20050991A2 (en)	2006-09-30
ES2311161T3 (es)	2009-02-01
ECSP056222A (es)	2006-04-19
JP2007500748A (ja)	2007-01-18
BRPI0411366A (pt)	2006-07-25
EP1654255B1 (de)	2008-08-27
EP1654255A1 (de)	2006-05-10
RS20050915A (sr)	2008-04-04
US20050004201A1 (en)	2005-01-06
CN1832940A (zh)	2006-09-13
IL172456A0 (en)	2006-04-10
ZA200600294B (en)	2007-04-25
EA200600032A1 (ru)	2006-06-30
US7439363B2 (en)	2008-10-21
DE602004016174D1 (de)	2008-10-09
KR20060021890A (ko)	2006-03-08
CR8148A (es)	2008-09-10
WO2005000836A1 (en)	2005-01-06
CO5650246A2 (es)	2006-06-30
IS8174A (is)	2005-12-09

Publication	Publication Date	Title
ATE406365T1 (de)	2008-09-15	Substituierte indazolyl(indolyl)maleimid-derivate als kinase inhibitoren
WO2009109991A3 (en)	2010-11-25	Novel hydrazide containing tyrosine kinase inhibitors
DE60119790D1 (de)	2006-06-22	Indazolyl-substituierte pyrrolidin-verbindungen als kinase inhibitoren
DE60213609D1 (de)	2006-09-14	THIENOi2,3-döPYRIMIDINEDIONES ALS INHIBITOREN VON T-ZELLEN-PROLIFERATION
EA200600509A1 (ru)	2006-08-25	Соединения пиримидотиофена
DE60304059D1 (de)	2006-05-11	3-(2-hydroxy-phenyl)-1h-pyrazol-4-carbonsäureamid derivate als hsp90 inhibitoren zur behandlung von krebs
ATE449099T1 (de)	2009-12-15	Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
EA200701302A1 (ru)	2007-12-28	4-(n-фениламино)хиназолины/-хинолины в качестве ингибиторов тирозинкиназы
GB0005357D0 (en)	2000-04-26	Compounds
YU84603A (sh)	2006-03-03	Novi inhibitori tirozin kinaze
MA31574B1 (fr)	2010-08-02	Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
DE60233884D1 (de)	2009-11-12	4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidon-derivate als pde-4-hemmer zur behandlung von neurologischen syndromen
NO911121D0 (no)	1991-03-20	Fremgangsmaate for fremstilling av nye skvalen-synetase-inhibitorer.
DE60228098D1 (de)	2008-09-18	Pyridin-substituierte furanderivate als raf-kinase inhibitoren
ATE368040T1 (de)	2007-08-15	Substituierte tetrazyklische pyprolochinolonderivate als phosphodiesterase- inhibitoren
EP1429771A4 (de)	2007-04-04	Bicyclische verbindungen als hemmer der chemokin-bindung an us28
ATE419242T1 (de)	2009-01-15	Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
ATE442354T1 (de)	2009-09-15	Pyrrolidinderivate als oxytocin antagonisten
DE60041001D1 (de)	2009-01-15	Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien
IL166164A0 (en)	2006-01-15	6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
DE60204468D1 (de)	2005-07-07	Thiopyran-4-one als inhibitoren der dna protein kinase
ATE353876T1 (de)	2007-03-15	Substituierte carbazole als inhibitoren von spla2
EA200100065A1 (ru)	2001-06-25	Производные гидроксамовой кислоты как ингибиторы продуцирования cd23 человека и высвобождения tnf

Legal Events

Date	Code	Title	Description
2009-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties